Influence of vanadium on serum lipid and lipoprotein profiles: a population-based study among vanadium exposed workers
© Zhang et al.; licensee BioMed Central Ltd. 2014
Received: 5 December 2013
Accepted: 19 February 2014
Published: 24 February 2014
Some experimental animal studies reported that vanadium had beneficial effects on blood total cholesterol (TC) and triglyceride (TG). However, the relationship between vanadium exposure and lipid, lipoprotein profiles in human subjects remains uncertain. This study aimed to compare the serum lipid and lipoprotein profiles of occupational vanadium exposed and non-exposed workers, and to provide human evidence on serum lipid, lipoprotein profiles and atherogenic indexes changes in relation to vanadium exposure.
This cross-sectional study recruited 533 vanadium exposed workers and 241 non-exposed workers from a Steel and Iron Group in Sichuan, China. Demographic characteristics and occupational information were collected through questionnaires. Serum lipid and lipoprotein levels were measured for all participants. The ratios of total cholesterol to high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) to HDL-C and apoB to apoA-I were used as atherogenic indexes. A general linear model was applied to compare outcomes of the two groups while controlling possible confounders and multivariate logistic regression was performed to evaluate the relationship between low HDL-C level, abnormal atherogenic index and vanadium exposure.
Higher levels of HDL-C and apoA-I could be observed in the vanadium exposed group compared with the control group (P < 0.05). Furthermore, atherogenic indexes (TC/HDL-C, LDL-C/HDL-C, and apoB/apoA-I ratios) were found statistically lower in the vanadium exposed workers (P < 0.05). Changes in HDL-C, TC/HDL-C, and LDL-C/HDL-C were more pronounced in male workers than that in female workers. In male workers, after adjusting for potential confounding variables as age, habits of smoking and drinking, occupational vanadium exposure was still associated with lower HDL-C (OR 0.41; 95% CI, 0.27-0.62) and abnormal atherogenic index (OR 0.38; 95% CI, 0.20-0.70).
Occupational vanadium exposure appears to be associated with increased HDL-C and apoA-I levels and decreased atherogenic indexes. Among male workers, a significantly negative association existed between low HDL-C level, abnormal atherogenic index and occupational vanadium exposure. This suggests vanadium has beneficial effects on blood levels of HDL-C and apoA-I.
KeywordsVanadium Lipid Lipoprotein Atherogenic index Occupational exposure
Vanadium is an inorganic trace element widely distributed throughout the lithosphere and biosphere . Though vanadium is present in drinking water and a variety of foods, whether it is an essential trace element for human beings has yet to be established with certainty [2–4]. Due to its wide application in ferrous metallurgy, atomic energy industry, aircraft construction, and chemical industry, the chance of vanadium exposure, both environmental and occupational, has been increasing [1, 5]. Therefore, a thorough understanding of possible beneficial and adverse effects from excessive vanadium exposure is critical.
Over the last several decades, biological actions of various vanadium compounds have been studied [6–8]. Most of the previous studies focused on the biological actions of vanadium compounds on improving glucose homeostasis and preserving insulin reserves [9–15], only a relatively small number of studies have associated vanadium exposure with altered lipid levels. Zychlinski  et al. found that long-term intratracheal administration of vanadium in rats was associated with pronounced decrease of the blood total cholesterol. Also, it has been demonstrated that vanadium significantly reduced triglyceride levels in experimental rats [10, 15]. Despite the evidence available regarding total cholesterol (TC) and triglyceride (TG) levels, it is unknown whether vanadium is also related to other parameters of lipid and lipoprotein profiles and atherogenic indexes (TC/HDL-C, LDL-C/HDL-C and apoB/apoA-I). Besides, there is no sufficient information about the relationship between vanadium exposure and lipid and lipoprotein profiles in human subjects in literature.
On the other hand, however, studies have confirmed that lipid and lipoprotein abnormalities play a major role in the pathogenesis and progression of atherosclerosis, cardiovascular disease and diabetes mellitus which are becoming growing health problems worldwide [17, 18]. Due to the increasing exposure facing around the world and the uncertain effects on lipid and lipoprotein, an in-depth study on vanadium-related lipid and lipoprotein changes become necessary.
So, by comparing the serum lipid and lipoprotein profiles of occupational vanadium exposed and non-exposed workers we undertook this population-based study to assess if serum lipid, lipoprotein profiles and atherogenic indexes changes were in relation to vanadium exposure.
Concentration of various lipid and lipoprotein in exposed and control group
Exposed group (N = 533)
Control group (N = 241)
Mean ± SD
Mean ± SD
4.28 ± 0.78
4.23 ± 0.78
1.44 ± 0.92
1.47 ± 1.00
1.36 ± 0.32
1.23 ± 0.25
2.92 ± 0.78
3.00 ± 0.79
2.32 ± 0.52
2.32 ± 0.55
1.55 ± 0.32
1.12 ± 0.18
0.74 ± 0.16
0.72 ± 0.15
0.34 ± 0.05
0.43 ± 0.08
1.50 ± 0.15
1.60 ± 0.20
3.31 ± 0.94
3.55 ± 0.93
1.81 ± 0.57
1.95 ± 0.58
0.50 ± 0.15
0.65 ± 0.17
Concentration of various lipids in exposed and control group in subgroups according to gender (Mean ± SD)
Female (N = 175)
Male (N = 599)
(n = 117)
(n = 58)
(n = 416)
(n = 183)
4.14 ± 0.71
4.00 ± 0.79
4.32 ± 0.79
4.30 ± 0.76
1.10 ± 0.57
0.96 ± 0.48
1.54 ± 0.97
1.63 ± 1.07
1.47 ± 0.30
1.39 ± 0.23
1.33 ± 0.32
1.18 ± 0.24
2.67 ± 0.30
2.61 ± 0.73
2.99 ± 0.79
3.12 ± 0.77
2.23 ± 0.50
2.15 ± 0.54
2.36 ± 0.53
2.37 ± 0.54
1.61 ± 0.31
1.15 ± 0.15
1.53 ± 0.31
1.11 ± 0.19
0.69 ± 0.14
0.64 ± 0.15
0.76 ± 0.16
0.74 ± 0.15
0.35 ± 0.05
0.47 ± 0.08
0.34 ± 0.05
0.42 ± 0.08
1.48 ± 0.14
1.56 ± 0.18
1.51 ± 0.15
1.61 ± 0.21
2.92 ± 0.69
2.93 ± 0.62
3.42 ± 0.97
3.75 ± 0.92
1.58 ± 0.46
1.58 ± 0.43
1.87 ± 0.58
2.06 ± 0.58
0.45 ± 0.14
0.56 ± 0.12
0.52 ± 0.15
0.68 ± 0.17
Multivariate analysis for low HDL-C level, abnormal atherogenic index and vanadium exposure among male workers
Low HDL-C Level
Abnormal Atherogenic Index
Odds Ratio (95% CI)
Odds Ratio (95% CI)
In this population-based study, we found that occupational vanadium exposure appears to be associated with increased HDL-C and apoA-I levels and decreased atherogenic indexes (TC/HDL-C, LDL-C/HDL-C and apoB/apoA-I). Furthermore, among male workers, exposure to vanadium was found to be significantly negatively associated with low HDL-C level and abnormal atherogenic index and this association cannot be attributed to confounding factors such as age, or unhealthy lifestyle (alcohol and tobacco consumption). This suggests vanadium may have beneficial effects on blood levels of HDL-C and apoA-I, which in a long term may reduce the risk of atherosclerosis.
Previous studies have demonstrated that a low plasma HDL-C concentration is a well-established risk factor for atherosclerosis and subsequent coronary heart disease, and several studies have reported higher concentrations of HDL-C in women compared to men [19–23]. According to our study, higher levels of HDL-C could be observed in the vanadium exposed group compared with the control group. What’s more interesting is when we stratified the study groups by gender, we found that compared with the control group, the exposed group had a much higher level of HDL-C in male workers, while in females, the levels showed no difference. A negative association still existed between vanadium exposure and low HDL-C level, independent of age, smoking and drinking. It seems that vanadium has a pronounced effect on male workers. Despite the well-documented gender difference and other identified metabolic factors responsible for the difference in HDL-C and apoA-I concentrations [20, 21], it remains to be elucidated whether it is because of susceptibility of the men. ApoA-I is the primary protein component of HDL and is a direct protect factor against atherosclerosis independent of HDL-C . ApoA-I facilitates selective uptake of HDL cholesterol by the liver by activating lecithin-cholesterol acyltransferase  and acting as a specific ligand for SR-BI . In our study, we found higher apoA-I level and smaller HDL-C/apoA-I in the vanadium exposure group. This suggests vanadium may mainly increase apoA-I by increasing the synthesis or by inhibiting its catabolism and accordingly increase the apoA-I-rich HDL-C level. But the mechanisms about how vanadium influences the HDL-C, apoA-I and HDL-C/apoA-I need more researches.
Furthermore, since lipid is a well-established risk factor for cardiovascular diseases and diabetes, the relationship between lipid, lipoprotein profiles and vanadium may provide another explanation for the effect of vanadium treatment on cardiovascular function in the hyperinsulinemic, insulin-resistant conditions. High values of atherogenic indexes (TC/HDL-C, LDL-C/HDL-C and apoB/apoA-I) have been reported to be risk factors for cardiovascular disease that led to insulin resistant [27–31]. According to our study, atherogenic indexes values were lower in vanadium exposure group than in control group, which may be one possible mechanism of its insulino-mimetic and anti-diabetic effects. Among male workers, a significantly negative association existed between occupational vanadium exposure and abnormal atherogenic index after adjusting for age, smoking and drinking. Whether it is because of longer services or the susceptibility of men remains to be elucidated.
The question as to how exactly vanadium causes lipid and lipoprotein alterations remains elusive. Vanadate is reported to decrease plasma cholesterol and inhibit cholesterol biosynthesis and this effect is ascribed to a possible inhibition of oxidase , which may be important in mediating lipid effects induced by vanadium. Biomedical importance of vanadium confirmed by numerous studies is mostly based on its interaction with proteins, including enzymatic systems and cellar constituents [32–34], which may influence the lipid and lipoprotein synthesis or interfere with catabolism. Also, the stimulation of lipoprotein lipase activity by vanadate and stimulation of 2,3-diphosphoglycerate hydrolysis by vanadium may play a role as well [35, 36].
This study finds that occupational exposure to vanadium in a low-dose, long-term exposure condition is associated with lipid and lipoprotein profiles alterations. One limitation of this study is that we did not have personal exposure measurements, which disabled us from further exploration of the relationship between lipids, lipoprotein levels and vanadium. In addition to occupational exposure measurements, biomarkers such as vanadium concentration in whole blood, serum, plasma or urine samples would be more accurate and convincing in terms of dose-response effects. Although it could be adjusted using statistical methods, higher prevalence of smoking and drinking in the exposed group could also be confounding variables. Lack of information on other factors known to influence lipid and lipoprotein levels such as levels of exercise and body mass index (BMI) may have an impact on the strength of the association. Also, because of the cross-sectional and observational nature of our study, results of this study should not be taken as evidence of a causal relationship. Future studies, preferably prospective cohort designs, are needed to clarify whether or not vanadium exposure leads to lipid and lipoprotein profiles changes, whether this effect is pronounced in certain subgroups such as the male workers and whether the association is dose-dependent. However, this study provides the initial epidemiological exploration demonstrating the association between vanadium exposure and altered lipid and lipoprotein profiles. The data may be of value for environmental exposure assessment of vanadium function.
In summary, our findings suggest that occupational exposure to vanadium appears to be associated with increased HDL-C and apoA-I levels and decreased atherogenic indexes values (TC/HDL-C, LDL-C/HDL-C and apoB/apoA-I). Among male workers, a significantly negative association existed between occupational vanadium exposure and low HDL-C level, abnormal atherogenic index after adjusting for age, smoking and drinking. This suggests vanadium may have beneficial effects on blood levels of HDL-C and apoA-I.
All the participants in this cross-sectional study were selected from an Iron and Steel Group in Sichuan, China. The exposed group comprised of 533 workers who had worked in the vanadium-containing steel production workshop for at least 1 year, whereas the workers of the control group (241) were recruited from a cold rolling workshop in the same corporation that produced the steel products without vanadium.
The two workshops were established at the same time around 1990. The cold rolling workshop is located about 3.1 miles away from the vanadium production workshop. Vanadium production workshop mainly manufactures vanadium pentoxide, vanadium trioxide and ferrovanadium. Other than vanadium, these two factories suffer from similar occupational hazard factors such as noise, thermal radiation, etc. Routine occupational safety monitoring data indicated that time-weighted average concentration of vanadium smoke was 0.216 mg/m3 in the exposed group, and 0.013 mg/m3 in the control group. Workers in both workshops were trained by the same vocational training school. Both groups had similar socioeconomic status (salary, education, etc.) and background environmental factors (diet, place of residence, etc.). For the vanadium-exposed group and controls, the mean ages were 37.5 ± 6.6 years (range: 21-59) old and 36.1 ± 5.5 years (range: 22-57) old, respectively. The prevalence of alcohol consumption (38.8% vs. 11.2%; P < 0.001) and smoking (45.2% vs. 23.2%; P < 0.001) was significantly higher among the exposed than among the controls.
All participants gave written informed consent at recruitment. The Ethics Review Board of the Medical Faculty of Sichuan University approved the study.
Main outcome measurements
Demographic characteristics and occupational information were collected through questionnaires. Blood samples were collected from an antecubital vein into vacutainer tube containing EDTA following a 12 h overnight. The concentrations of total cholesterol (TC) and triglyceride (TG) in the serum were determined by an enzymatic colorimetric method . The HDL-C level was measured in the supernatant after precipitation of apoB containing lipoproteins with heparin-manganese chloride . The concentration of low-density lipoprotein cholesterol (LDL-C) was determined according to the Friedewald formula . ApoB was determined by a 2-site immunoradiometric assay and apoA-I by a competitive radioimmunoassay, using commercial kits from Pharmacia (Uppsala, Sweden). The coefficients of variation for all lipid parameters were <5%.
Definition of terms
The ratios of TC to HDL-C (TC/HDL-C), LDL-C to HDL-C (LDL-C/HDL-C) and apoB to apoA-I (apoB/apoA-I) were used as the atherogenic indexes. The parameter HDL-C < 1.04 mmol/l was considered abnormal. Abnormal atherogenic index was defined as TC/HDL-C > 5, and/or LDL-C/HDL-C > 3, and/or apoB/apoA-I > 0.9.
The R software from the “The Comprehensive R Archive Network” was used to perform all statistical processing. The results are presented as mean ± SD. Differences between groups were evaluated using analysis of covariance for continuous variables. Multivariate logistic regression model was used to evaluate associations between low HDL-C levels, abnormal atherogenic index and vanadium exposure, with odd ratios and 95% confidence intervals estimated. The significant level was 0.05 (two-tailed).
This study was supported by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry. The authors thank all the workers and management personnel participated in this study, and to those all who provided help to this study.
- Barceloux DG, Barceloux D: Vanadium. Clin Toxicol. 1999, 37 (2): 265-278. 10.1081/CLT-100102425.
- Habib HM, Ibrahim WH: Nutritional quality of 18 date fruit varieties. Int J Food Sci Nutr. 2011, 62 (5): 544-551. 10.3109/09637486.2011.558073View ArticlePubMed
- Hopkins L, Mohr H: Vanadium as an essential nutrient. Federation proceedings. 1974, 33 (6): 1773-1775.PubMed
- Sullivan MJ, Leavey S: Heavy metals in bottled natural spring water. J Environ Health. 2011, 73 (10): 8-13.PubMed
- Services RI: Vanadium: global industry markets and outlook. Roskill Inform Serv Ltd. 2013,
- Nechay BR: Mechanisms of action of vanadium. Ann Rev Pharmacol Toxicol. 1984, 24: 501-524. 10.1146/annurev.pa.24.040184.002441.View Article
- Jandhyala BS, Hom GJ: Minireview: physiological and pharmacological properties of vanadium. Life Sci. 1983, 33 (14): 1325-1340. 10.1016/0024-3205(83)90816-0View ArticlePubMed
- Ramasarma T, Crane FL: Does vanadium play a role in cellular regulation?. Curr Topics Cell Regulat. 1981, 20: 247-301.View Article
- Brichard SM, Bailey CJ, Henquin JC: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes. 1990, 39 (11): 1326-1332. 10.2337/diab.39.11.1326View ArticlePubMed
- Jelikic-Stankov M, Uskokovic-Markovic S, Holclajtner-Antunovic I, Todorovic M, Djurdjevic P: Compounds of Mo, V and W in biochemistry and their biomedical activity. J Trace Elem Med Biol. 2007, 21 (1): 8-16. 10.1016/j.jtemb.2006.11.004View ArticlePubMed
- Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard SM: Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br J Pharmacol. 1999, 126 (2): 467-477. 10.1038/sj.bjp.0702311PubMed CentralView ArticlePubMed
- Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes. 1990, 39 (1): 1-5. 10.2337/diacare.39.1.1View ArticlePubMed
- Srivastava AK, Mehdi MZ: Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med. 2005, 22 (1): 2-13. 10.1111/j.1464-5491.2004.01381.x.View ArticlePubMed
- Verma S, Cam MC, McNeill JH: Nutritional factors that that favorably influence the glucose/insulin system: Vanadium. J Am Coll Nutr. 1998, 17 (1): 11-18. 10.1080/07315724.1998.10718730View ArticlePubMed
- Wasan KM, Risovic V, Yuen VG, McNeill JH: Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds. J Trace Elem Med Biol. 2006, 19 (4): 251-258. 10.1016/j.jtemb.2005.10.001View ArticlePubMed
- Zychlinski L, Byczkowski JZ, Kulkarni AP: Toxic effects of long-term intratracheal administration of vanadium pentoxide in rats. Arch Environ Contaminat Toxicol. 1991, 20 (3): 295-298. 10.1007/BF01064393.View Article
- Chrysohoou C, Panagiotakos DB, Pitsavos C, Kosma K, Barbetseas J, Karagiorga M, Ladis I, Stefanadis C: Distribution of serum lipids and lipoproteins in patients with beta thalassaemia major; an epidemiological study in young adults from Greece. Lipids Health Dis. 2004, 3: 3-3. 10.1186/1476-511X-3-3PubMed CentralView ArticlePubMed
- Ginsberg HN: Lipoprotein metabolism and its relationship to atherosclerosis. Med Clin North Am. 1994, 78 (1): 1-20.PubMed
- Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM, Patsch W: Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thrombosis. 1993, 13 (8): 1139-1158. 10.1161/01.ATV.13.8.1139.View Article
- Ohta T, Hattori S, Murakami M, Nishiyama S, Matsuda I: Age- and sex-related differences in lipoproteins containing apoprotein A-I. Arterioscler (Dallas, Tex). 1989, 9 (1): 90-95. 10.1161/01.ATV.9.1.90.View Article
- Pascot A, Lemieux I, Bergeron J, Tremblay A, Nadeau A, Prud’homme D, Couillard C, Lamarche B, Despres JP: HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis. 2002, 160 (2): 399-406. 10.1016/S0021-9150(01)00579-2View ArticlePubMed
- Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ: Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec cardiovascular study. Atherosclerosis. 1996, 119 (2): 235-245. 10.1016/0021-9150(95)05653-XView ArticlePubMed
- Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B: HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis. 2000, 153 (2): 263-272. 10.1016/S0021-9150(00)00603-1View ArticlePubMed
- Francis MC, Frohlich JJ: Coronary artery disease in patients at low risk - apolipoprotein AI as an independent risk factor. Atherosclerosis. 2001, 155 (1): 165-170. 10.1016/S0021-9150(00)00528-1View ArticlePubMed
- Jonas A: Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochimica et Biophysica Acta (BBA)-Lipids Lipid Metab. 1991, 1084 (3): 205-220. 10.1016/0005-2760(91)90062-M.View Article
- Williams DL, Temel RE, Connelly MA: Roles of scavenger receptor BI and APO AI in selective uptake of HDL cholesterol by adrenal cells. Endocrine Res. 2000, 26 (4): 639-651. 10.3109/07435800009048584. 10.3109/07435800009048584View Article
- Jeppesen J, Facchini FS, Reaven GM: Individuals with high total cholesterol HDL cholesterol ratios are insulin resistant. J Intern Med. 1998, 243 (4): 293-298. 10.1046/j.1365-2796.1998.00301.xView ArticlePubMed
- Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, Despres JP: Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men - the Quebec cardiovascular study. Arch Intern Med. 2001, 161 (22): 2685-2692. 10.1001/archinte.161.22.2685View ArticlePubMed
- Walldius G, Jungner I: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med. 2006, 259 (5): 493-519. 10.1111/j.1365-2796.2006.01643.xView ArticlePubMed
- Walldius G, Jungner I: Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004, 255 (2): 188-205. 10.1046/j.1365-2796.2003.01276.xView ArticlePubMed
- Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW: Increased apoB/A-I ratio independently associated with Type 2 diabetes mellitus: cross-sectional study in a Korean population. Diabet Med. 2012, 29 (9): 1165-1170. 10.1111/j.1464-5491.2012.03622.xView ArticlePubMed
- Bevan AP, Drake PG, Yale JF, Shaver A, Posner BI: Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol Cell Biochem. 1995, 153 (1–2): 49-58.View ArticlePubMed
- Grillo S, Gremeaux T, Casamayor A, Alessi DR, Le Marchand-Brustel Y, Tanti JF: Peroxovanadate induces tyrosine phosphorylation of phosphoinositide-dependent protein kinase-1 - Potential involvement of Src kinase. Eur J Biochem. 2000, 267 (22): 6642-6649. 10.1046/j.1432-1327.2000.01759.xView ArticlePubMed
- Thompson KH, McNeill JH, Orvig C: Vanadium compounds as insulin mimics. Chem Rev. 1999, 99 (9): 2561-2571. 10.1021/cr980427cView ArticlePubMed
- Ueki H, Sera M, Tanaka K: Stimulatory release of lipoprotein lipase activity from rat fat pads by vanadate. Arch Biochem Biophys. 1989, 272 (1): 18-24. 10.1016/0003-9861(89)90189-6View ArticlePubMed
- Stankiewicz PJ: Vanadium(IV)-stimulated hydrolysis of 2, 3-diphosphoglycerate. Arch Biochem Biophys. 1989, 270 (2): 489-494. 10.1016/0003-9861(89)90530-4View ArticlePubMed
- Omodeo Sale F, Marchesini S, Fishman PH, Berra B: A sensitive enzymatic assay for determination of cholesterol in lipid extracts. Analyt Biochem. 1984, 142 (2): 347-350. 10.1016/0003-2697(84)90475-5View ArticlePubMed
- Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, Breckenridge C, Chow A, Kuba K, Weidman S, Arnett H, Wood P, Shlagenhaft A: Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem. 1978, 24 (6): 853-856.PubMed
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18 (6): 499-502.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.